As of mid-February, no antiviral drugs or vaccine candidates have proven effective against SARS-CoV-2, but there are antivirals in the pipeline that may have potential. The first trials of the investigational drug remdesivir are underway. There is no combination effective treatment with any specific cure. The primary focus is on supportive treatments and preventing and treating complications. In cases where a virus is detected early and the disease is mild, the recommended preventive approach is minimal, including limiting exposure, as well as basic hygiene and hand washing. The recommended course of action on the basis of the U.S.
Signs and symptoms of acute respiratory infection due to SARS and MERS are similar to clinical presentations of COVID-19, most commonly the flu, with fever, fatigue, myalgia, headache and a cough. Diarrhea may be the first symptom for COVID-19, and patients with diarrhea have a more recent age of onset.
Contrary to what was previously believed, there is no evidence that COVID-19 can be cured. The disease will likely to be lethal in most cases for the majority of people.
As of March 10, 2020, approximately 1.3million people have been reported to have the disease, and there has not been a single reported death. As is typically the case with infectious disease outbreaks, a number of cases occur each year. In the case of coronavirus (CoV-19), estimates depend upon the model used, with the highest estimates reported by the "Times" and "Washington Post" based upon their respective models. The model used by the "Times" was reflective of the best estimates, while the model used by the "Washington Post" was reflective of the worst estimates, as these respective papers used different models. The predictions by both of these papers were then combined.
There is evidence that the current guidelines for treatment of SARS are only loosely informed by the literature and that most commonly employed treatments may be of limited benefit. There is an urgent need for clinical trials to support the effectiveness of most commonly employed therapeutic measures.
The outbreak of the 2019-20 coronavirus is the first, and thus far only, widespread epidemic of a coronavirus in human history. Of the seven novel, SARS-CoV-2. The epidemiology and clinical impact of the disease remain unknown, and the disease is caused by a novel coronavirus (CoV), the 2019-Coronavirus (SARS-CoV2).
This paper presents case histories of a series of 9 patients with C19-related disease. The diagnosis was supported by molecular detection in four of the nine and in the absence of such detection, by clinical data in the other five. There was a temporal relationship with an increased exposure to coronaviruses in March 2019. C19 has been reported from China in April 2019, confirming virus persistence in an area with few cases until April. This is the first documentation of C19 in a high-incidence area, and has further suggested it might have broader relevance.
Current research indicates that catechol-O-methyltransferase genetic variation contributes significantly to cognitive performance. Findings from a recent study may be useful for planning clinical trials for future cases such as covid-19. A clinical trial for covid-19 should be encouraged when the impact on human cognitive performance is significant and where the current treatment options are either suboptimal or nonexistent.
A single, brief outpatient treatment for those with covid-19 resulted in improvements to several aspects of quality of life. Future studies are needed to confirm that these results are sustained outside the lab setting.
According to the World Health Organization (WHO), "[c]ontroversy remains about whether [covid-19] will have a severe impact on health." At the moment we lack sufficient evidence to estimate risks for patients with [covid-19] relative to risks of untreated disease in those infected. We use the WHO's severity classification of mild, moderate, severe and critical and we aim to provide practical advice and to highlight the need for additional research. The severity of [covid-19] is not related to the number of [covid-19] cases. We show the impact that [covid-19] had on hospitals in the UK.
The present analysis confirms that influenza and pneumonia usually cause disease symptoms, but also the more rarer diagnoses of encephalitis, meningitis, and acute flaccid myelitis. Many symptoms can be treated via antiviral agents, but the need for admission to hospital in cases of non-infectious disease justifies considering additional imaging. These are the easiest ways to recognize conditions and to make appropriate therapeutic decisions.
Currently there are trials underway to test the hypothesis that treatment of patients infected with COVID may work, and this treatment could potentially also be used to other similar respiratory infections that can be carried by SARS-CoV-2. There are ongoing and promising studies to evaluate whether it is possible and safe to treat this infectious disease.